Dyadic CEO Mark Emalfarb, Chief Scientic Officer Ronen Tchelet to present at industry events this month

Dyadic International Inc (NASDAQ:DYAI) announced Monday that the company will be presenting at a plethora of upcoming investor and industry events this month.  CEO Mark Emalfarb and Chief Scientific Officer Ronen Tchelet will present at the following events: 3:30 pm ET September 14 — HC Wainwright 22nd Annual Global Investment Conference (Emalfarb) 10:10 am ET September 22 — BPI East (Tchelet) 1:45 pm ET September 23 — Sidoti & Company Conference (Emalfarb) 2:10 pm ET and 4:40 pm September 29, 4:20 pm September 30 and 3:05 pm October 1 — World Vaccine Congress (Emalfarb and Tchelet) READ: Dyadic reveals rising R&D revenue in 2Q results from a bevy of research collaborations At the WVC, Emalfarb will lead the September 29th presentations, titled “Novel Industrially Proven Hyper Productive C1 Expression System for Biotherapeutics such as Vaccines & Antibodies” and “How do you meet the demand of low-cost manufacturing using new vaccine modalities?”  Tchelet will lead the presentations on September 30th and October 1, titled “Novel Recombinant Influenza Platform - C1 Gene Expression Platform / Speeding the Development, Lowering the Cost & Improving the Performance of Flu Vaccines” and “Accelerating Development, Lowering Costs and Improving the Performance of Recombinant Vaccines, Antigens & Vlp's,” respectively.  Dyadic management will be available during the events for one-one-one meetings, the company said. Interested investors and industry partners may request a one-on-one meeting at jlatiuk@dyadic.com or (561) 743-8333. Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com Follow him on Twitter @andrew_kessel